IL161327D0 - Methods for treating ocular neovascular diseases - Google Patents

Methods for treating ocular neovascular diseases


Publication number
IL161327D0 IL16132702A IL16132702A IL161327D0 IL 161327 D0 IL161327 D0 IL 161327D0 IL 16132702 A IL16132702 A IL 16132702A IL 16132702 A IL16132702 A IL 16132702A IL 161327 D0 IL161327 D0 IL 161327D0
Prior art keywords
treating ocular
neovascular diseases
ocular neovascular
Prior art date
Application number
Original Assignee
Eyetech Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US33230401P priority Critical
Application filed by Eyetech Pharmaceuticals filed Critical Eyetech Pharmaceuticals
Priority to PCT/US2002/035986 priority patent/WO2003039404A2/en
Publication of IL161327D0 publication Critical patent/IL161327D0/en


IL16132702A 2001-11-09 2002-11-08 Methods for treating ocular neovascular diseases IL161327D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US33230401P true 2001-11-09 2001-11-09
PCT/US2002/035986 WO2003039404A2 (en) 2001-11-09 2002-11-08 Methods for treating ocular neovascular diseases

Publications (1)

Publication Number Publication Date
IL161327D0 true IL161327D0 (en) 2004-09-27



Family Applications (1)

Application Number Title Priority Date Filing Date
IL16132702A IL161327D0 (en) 2001-11-09 2002-11-08 Methods for treating ocular neovascular diseases

Country Status (26)

Country Link
US (3) US20030171320A1 (en)
EP (1) EP1441743A4 (en)
JP (1) JP2005511576A (en)
KR (1) KR20050044372A (en)
CN (1) CN1582156A (en)
AP (1) AP1750A (en)
AR (1) AR037307A1 (en)
BR (1) BR0213975A (en)
CA (1) CA2464007A1 (en)
CR (1) CR7330A (en)
EA (1) EA006746B1 (en)
EC (1) ECSP045098A (en)
GE (1) GEP20063755B (en)
HR (1) HRP20040406A2 (en)
IL (1) IL161327D0 (en)
IS (1) IS7215A (en)
MA (1) MA27145A1 (en)
MX (1) MXPA04004363A (en)
NO (1) NO20041882L (en)
OA (1) OA12720A (en)
PL (1) PL371929A1 (en)
RS (1) RS35404A (en)
TN (1) TNSN04081A1 (en)
TW (1) TWI260327B (en)
WO (1) WO2003039404A2 (en)
ZA (1) ZA200402753B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530146A (en) * 2000-02-10 2003-10-14 マサチューセッツ・アイ・アンド・イア・インファーマリー Photodynamic therapy for treating conditions of the eye
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
US6942655B2 (en) * 2001-11-13 2005-09-13 Minu, Llc Method to treat age-related macular degeneration
WO2004080284A2 (en) * 2003-03-07 2004-09-23 Board Of Regents, The University Of Texas System Antibody-targeted photodynamic therapy
CL2004001996A1 (en) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Anti-VEGF aptamers (vascular endothelial growth factor) with blocking nucleotide 5'-5 'or 3'-3' inverted, composition containing it, useful for disorders neovascularization.
CA2903196A1 (en) 2003-08-27 2005-03-10 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7575321B2 (en) 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
AT418325T (en) 2004-01-20 2009-01-15 Allergan Inc Compositions for the localized treatment of the eye, preferably containing triamcinolone acetonide and hyaluronic acid
EP1732571A4 (en) * 2004-03-05 2009-09-09 Archemix Corp Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
EP1765362B1 (en) * 2004-06-04 2012-03-28 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases
US7785784B2 (en) * 2004-07-23 2010-08-31 Eyetech, Inc. Detection of oligonucleotides by dual hybridization
JP2006056807A (en) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc Preparation for use in photodynamic therapy
AU2012200865A1 (en) * 2004-10-21 2012-03-29 Genentech, Inc. Method for treating intraocular neovascular diseases
EP2319492A3 (en) * 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2006047716A2 (en) * 2004-10-26 2006-05-04 Bioresponse Llc Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease
EP1827462A4 (en) * 2004-11-24 2012-01-04 Therakine Ltd An implant for intraocular drug delivery
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP3025713A1 (en) 2005-02-09 2016-06-01 Santen Pharmaceutical Co., Ltd Liquid formulations for treatment of diseases or conditions
JP2008533204A (en) * 2005-03-21 2008-08-21 マクサイト, インコーポレイテッド Drug delivery system for the treatment of a disease or condition
US20060293270A1 (en) * 2005-06-22 2006-12-28 Adamis Anthony P Methods and compositions for treating ocular disorders
WO2007037188A1 (en) * 2005-09-27 2007-04-05 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CA2622312A1 (en) * 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US20070218007A1 (en) * 2006-03-17 2007-09-20 Allergan, Inc. Ophthalmic visualization compositions and methods of using same
CA2645488C (en) 2006-03-23 2014-09-02 Macusight, Inc. Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
EP2029103A2 (en) * 2006-06-16 2009-03-04 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
WO2008103320A1 (en) * 2007-02-16 2008-08-28 Novacea, Inc. Methods of treating ophthalmic disorders with anthraquinones
JP2008308488A (en) * 2007-05-11 2008-12-25 Santen Pharmaceut Co Ltd Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
WO2009054914A1 (en) * 2007-10-19 2009-04-30 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
EP2349339A4 (en) * 2008-10-16 2015-01-07 Kathleen Cogan Farinas Sustained drug delivery system
US8530189B2 (en) * 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
KR101692459B1 (en) 2008-12-16 2017-01-03 밸리언트 파마슈티컬즈 인터내셔널, 인코퍼레이션 Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
WO2010091234A2 (en) * 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
ES2468827T3 (en) * 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd pharmaceutical for preventing or treating ocular disorders with angiognesis and / or high ocular vascular permeability
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
MX349901B (en) 2011-01-13 2017-08-18 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders.
CN103391782A (en) 2011-02-02 2013-11-13 公立大学法人名古屋市立大学 Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
CN103721257B (en) * 2012-10-16 2016-12-21 无锡兆真辐射技术有限公司 Photofrin catalytic decomposition of hydrogen peroxide series pharmaceutical
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
RU2527360C1 (en) * 2013-04-23 2014-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации Method for combination therapy of retinovascular macular oedema
EP3086809A4 (en) * 2013-12-24 2017-11-29 NovelMed Therapeutics, Inc. Compositions and methods of treating ocular diseases
DE102017008721A1 (en) 2017-09-16 2019-03-21 protectismundi GmbH Method and apparatus for Hochhausbrandbekämfpung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259188T3 (en) * 1996-10-25 2006-09-16 Gilead Sciences, Inc. Ligand Complexes nucleic acid vascular endothelial growth factor (VEGF).
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
WO1995024930A1 (en) * 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
JP3845469B2 (en) * 1996-02-21 2006-11-15 明治製菓株式会社 Dosage for use in occlusion of the retinal neovasculature
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
JP2003519670A (en) * 2000-01-12 2003-06-24 ライト サイエンシーズ コーポレイション A new treatment of eye disease
JP2003530146A (en) * 2000-02-10 2003-10-14 マサチューセッツ・アイ・アンド・イア・インファーマリー Photodynamic therapy for treating conditions of the eye
AT375141T (en) * 2000-03-10 2007-10-15 Insite Vision Inc Method and agent for the treatment and prevention of diseases of the posterior chamber
WO2001074389A2 (en) * 2000-03-24 2001-10-11 Novartis Ag Improved treatment of neovascularization
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
WO2004034889A2 (en) * 2002-10-18 2004-04-29 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization

Also Published As

Publication number Publication date
AR037307A1 (en) 2004-11-03
KR20050044372A (en) 2005-05-12
BR0213975A (en) 2005-05-10
ECSP045098A (en) 2004-07-23
CA2464007A1 (en) 2003-05-15
PL371929A1 (en) 2005-07-11
US20070027101A1 (en) 2007-02-01
EA200400518A1 (en) 2004-12-30
WO2003039404A3 (en) 2004-02-12
GEP20063755B (en) 2006-02-27
TW200302226A (en) 2003-08-01
CR7330A (en) 2005-06-15
EP1441743A2 (en) 2004-08-04
CN1582156A (en) 2005-02-16
MA27145A1 (en) 2005-01-03
MXPA04004363A (en) 2005-05-16
AP1750A (en) 2007-06-23
AP200403026A0 (en) 2004-06-30
OA12720A (en) 2006-06-27
TNSN04081A1 (en) 2006-06-01
EA006746B1 (en) 2006-04-28
JP2005511576A (en) 2005-04-28
ZA200402753B (en) 2005-01-05
EP1441743A4 (en) 2009-02-25
NO20041882L (en) 2004-05-07
US20040167091A1 (en) 2004-08-26
TWI260327B (en) 2006-08-21
RS35404A (en) 2006-10-27
US20030171320A1 (en) 2003-09-11
IS7215A (en) 2004-04-07
HRP20040406A2 (en) 2005-02-28
WO2003039404A2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
AP1635A (en) Azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease
HRP20040042A2 (en) Substituted oxazolidinones for combinational therapy
AU1294401A (en) Methods for treating fibroproliferative diseases
AU2002359687A8 (en) Multiple laser treatment
HK1062636A1 (en) Combination therapy
AU1164902A (en) Targeted therapeutic agents
PL363946A1 (en) Pyrazolopyrimidines as therapeutic agents
PL363740A1 (en) Pyrazolopyrimidines as therapeutic agents
IL158921D0 (en) Anti-ngf antibodies for the treatment of various disorders
AUPQ514600A0 (en) Brain injury treatment
AU2003304386A1 (en) Methods for treating and preventing apoptosis-related diseases using rna interfering agents
GB0107175D0 (en) Chassis for grass treatment machine
AU2002258754A1 (en) Glaucoma stent and methods thereof for glaucoma treatment
EP1416961A4 (en) Composition and method for the treatment of disease
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
EP1441685A4 (en) Anti-irritating rosacea treatment
EP1434603A4 (en) Method of treatment using ligand-immunogen conjugates
GB0028264D0 (en) Well treatment
IL251270D0 (en) Cancer treatment
GB0128108D0 (en) Therapeutic use
GB0104383D0 (en) Cancer Treatment
EP1463438A4 (en) Endomural therapy
IL160933D0 (en) Methods and compositions for treating ?cap associated diseases
ZA200306175B (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
HK1059564A1 (en) Indanylderivatives for treating airway diseases